Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant Recipients

Recruiting now · Phase 4 · Has a placebo group

Conditions studied: CMV, Lung Transplant Recipient

In brief

The primary objective of the CLEAR-CMV trial is to evaluate the efficacy of letermovir therapy plus standard of care (SOC) antiviral compared to SOC plus placebo in achieving clearance of CMV viremia by week 3 in lung transplant recipients with active CMV infection.

Key facts

Study ID

NCT07235683

Run by

University Health Network, Toronto

People needed

40

Starts

2025-12-24

Expected to finish

2027-08-01

Last updated by the study team

2026-02-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Recipient of a lung transplant.
• Has confirmed CMV viremia with a viral load ≥ 1000 IU/mL and will receive or has just started SOC antiviral treatment in the past 72h as per the decision of the treating physician.

You may not qualify if…

• Renal failure with Creatinine clearance <15 mL/min or requiring dialysis
• Severe hepatic impairment (Child-Pugh Class C)
• Participating in another interventional clinical trial
• Combined transplant (e.g heart-lung, lung-liver)
• Known allergy or contraindication to any of the antiviral medications
• Known antiviral resistance.
• Patient receiving cyclosporin, pimozide or ergot alkaloids (due to significant drug interaction with letermovir).
• Patient receiving or expected to receive CMV immunoglobulin or IVIG during the initial three week treatment phase

Where it is running

• University Health Network, Toronto General Hospital — Toronto, Ontario, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.